Swiss drug major Novartis AG (NVS) said that the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency has adopted a positive opinion recommending approval of Tafinlar, or dabrafenib, in combination with Mekinist, or trametinib, for the adjuvant treatment of adult patients with stage III melanoma with a BRAF V600 mutation, following complete resection.
from RTT - Biotech https://ift.tt/2NPryWl
via IFTTT
No comments:
Post a Comment